Adenocarcinoma of Sigmoid Colon

Treatment for locally advanced adenocarcinoma of the sigmoid colon in elderly patients requires careful consideration of patient comorbidities and performance status. Generally, the approach mirrors that of younger patients, involving multidisciplinary management. Surgical resection remains the cornerstone of treatment, aiming for complete tumor removal with adequate margins. For T3/T4 tumors or node-positive disease, adjuvant chemotherapy with regimens such as FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) or CAPOX (capecitabine, oxaliplatin) may be considered, often with dose adjustments based on patient tolerance. Radiation therapy can be utilized in select cases, particularly for locally advanced rectal tumors or those with positive margins post-surgery. Neoadjuvant chemoradiation followed by surgery and adjuvant chemotherapy is sometimes considered for locally advanced rectal tumors to improve resectability. Targeted therapies such as bevacizumab or cetuximab may be incorporated depending on molecular profiling (KRAS, NRAS, BRAF) and patient suitability. Ultimately, treatment decisions must be individualized through shared decision-making, balancing treatment efficacy with potential toxicity in this vulnerable population. Explore how geriatric oncology principles can further refine treatment strategies for these patients.

Differentiating diverticulitis and sigmoid colon cancer on CT can be challenging, as both can present with bowel wall thickening and pericolic inflammation. Key features suggestive of sigmoid colon cancer include a focal, irregular mass, asymmetric bowel wall thickening, and pericolonic fat stranding with a "shouldering" effect adjacent to the mass. Diverticulitis typically presents with more diffuse, concentric bowel wall thickening, associated with diverticula, and inflammation often confined to the pericolic fat surrounding the diverticula. The presence of lymphadenopathy, distant metastases, or bowel obstruction favors malignancy. However, overlapping imaging features can occur, requiring careful consideration of clinical presentation, laboratory findings (e.g., CEA levels), and potentially further investigations such as colonoscopy with biopsy for definitive diagnosis. Consider implementing a standardized radiological reporting template for improved diagnostic accuracy. Learn more about the utility of advanced imaging techniques, such as MRI or PET/CT, in challenging cases.

Post-resection surveillance for sigmoid colon adenocarcinoma aims to detect recurrence early and improve patient outcomes. Guidelines generally recommend history and physical examination every 3-6 months for the first 2-3 years, then every 6-12 months for up to 5 years. CEA levels should be checked every 3-6 months for the first 2-3 years. Colonoscopy is recommended one year after surgery, then repeated at years 3 and 5, or sooner if polyps are detected. CT scans of the chest, abdomen, and pelvis are typically performed annually for the first 3-5 years, particularly in patients with stage II or III disease. The frequency and duration of surveillance may be tailored based on individual risk factors, such as TNM stage, tumor grade, and presence of lymphovascular invasion. Regular follow-up with an oncologist is crucial for ongoing assessment and management of any potential complications or recurrence. Learn more about the role of emerging biomarkers and liquid biopsies in improving surveillance strategies.